Please find below a list of trials that are currently accruing:
- A Phase I/II Study of SNDX-5613 in People with Recurrent or Persistent Acute Leukemia
- A Phase IB/II Study of KRT-232 and Cytarabine or Decitabine in People with Acute Myeloid Leukemia
- A Phase I Study of CB-5339 for Recurrent or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndromes
- A Phase I Study of CG-806 in People with Acute Myeloid Leukemia
- A Phase I Study of LY3410738 in Patients with Advanced Blood Cancers with IDH1 or IDH2 Mutations
- A Phase IA/IB Study of TTI-622 Immunotherapy in Patients with Advanced Persistent or Recurrent Blood Cancers
- A Phase I Study of BTX-1188 in People with Acute Myeloid Leukemia
- A Phase IB/II Study of Lanraplenib in Combination with Gilteritinib in People with FLT3-Mutated Recurrent or Persistent Acute Myeloid Leukemia
- A Phase I Study of TP-3654 in People with Myelofibrosis
If you would like to contact us or refer a patient, please call 646-608-3749.